22722 29TH DR. SE, SEATTLE, WA
Changes in Board, Management or Compensation
Reports Second Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program
Announces Pricing of $45.0 Million Underwritten Public Offering
Submission of Matters to a Vote of Security Holders
Reports First Quarter 2025 Financial Results and Highlights Updates in Cytisinicline Program
Annual Report to Security Holders
Earnings Release
Q2
Q1
FY 2024
Q3
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
PRE 14A
PRER14A
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Post-Effective Amendment to Registration Statement